[
FCH
FEC
PET-CT
hyperparathyroidism
parathyroid adenoma
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
13 Apr 2021
13 Apr 2021
Historique:
received:
17
02
2021
revised:
16
03
2021
accepted:
25
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
The diagnostic performance of [ Patients in whom US and MS delivered either incongruent or entirely negative findings were subjected to FEC-PET&4D-CT and cases from July 2017 to June 2020 were analyzed, retrospectively. Cervical exploration with intraoperative PTH-monitoring (IO-PTH) was performed. Imaging results were correlated to intraoperative findings, and short term and one year postoperative follow-up data. From July 2017 to June 2020 in 171 FEC-PET&4D-CTs 159 (92.9%) PAs were suggested. 147 patients already had surgery, FEC-PET&4D-CT accurately localized in 141; false neg. 4, false pos. 2, global sensitivity 0.97; accuracy 0.96, PPV 0.99. All of the 117 patients that already have completed their 12-month postoperative follow up had normal biochemical parameter, i.e., no signs of persisting disease. However, two cases may have a potential for recurrent disease, for a cure rate of at least 98.3%. FEC-PET&4D-CT shows unprecedented results regarding the accuracy localizing PAs. The one-year-follow-up data demonstrate a high cure rate. We, therefore, suggest FEC-PET-CT as the relevant diagnostic tool for the localization of PAs when US fails to localize PA, especially after previous surgery to the neck.
Sections du résumé
BACKGROUND
BACKGROUND
The diagnostic performance of [
METHODS
METHODS
Patients in whom US and MS delivered either incongruent or entirely negative findings were subjected to FEC-PET&4D-CT and cases from July 2017 to June 2020 were analyzed, retrospectively. Cervical exploration with intraoperative PTH-monitoring (IO-PTH) was performed. Imaging results were correlated to intraoperative findings, and short term and one year postoperative follow-up data.
RESULTS
RESULTS
From July 2017 to June 2020 in 171 FEC-PET&4D-CTs 159 (92.9%) PAs were suggested. 147 patients already had surgery, FEC-PET&4D-CT accurately localized in 141; false neg. 4, false pos. 2, global sensitivity 0.97; accuracy 0.96, PPV 0.99. All of the 117 patients that already have completed their 12-month postoperative follow up had normal biochemical parameter, i.e., no signs of persisting disease. However, two cases may have a potential for recurrent disease, for a cure rate of at least 98.3%.
CONCLUSION
CONCLUSIONS
FEC-PET&4D-CT shows unprecedented results regarding the accuracy localizing PAs. The one-year-follow-up data demonstrate a high cure rate. We, therefore, suggest FEC-PET-CT as the relevant diagnostic tool for the localization of PAs when US fails to localize PA, especially after previous surgery to the neck.
Identifiants
pubmed: 33924371
pii: jcm10081648
doi: 10.3390/jcm10081648
pmc: PMC8068905
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA Surg. 2013 Feb;148(2):109-15
pubmed: 23560281
Endocrine. 2021 Feb;71(2):285-297
pubmed: 32892309
Ann Surg Oncol. 2012 Dec;19(13):4202-9
pubmed: 22825773
JAMA Surg. 2016 Oct 1;151(10):959-968
pubmed: 27532368
Ann Surg. 2004 May;239(5):704-8; discussion 708-11
pubmed: 15082975
Lancet. 2009 Jul 11;374(9684):145-58
pubmed: 19595349
Exp Clin Endocrinol Diabetes. 2020 Oct;128(10):693-698
pubmed: 31412376
Exp Clin Endocrinol Diabetes. 1999;107(6):331-6
pubmed: 10543408
World J Surg. 2014 Sep;38(9):2304-10
pubmed: 24728582
Surg Clin North Am. 2004 Jun;84(3):717-34
pubmed: 15145230
Chirurg. 2005 Mar;76(3):207-16
pubmed: 15678302
Zentralbl Chir. 2020 Apr;145(2):168-175
pubmed: 30795026
Radiology. 2014 Jan;270(1):15-24
pubmed: 24354373
Ann Surg. 1976 Oct;184(4):391-402
pubmed: 1015886
Arch Surg. 2002 Sep;137(9):1055-9
pubmed: 12215160
Eur J Surg Oncol. 2017 Jan;43(1):133-137
pubmed: 27776943
Updates Surg. 2017 Jun;69(2):161-169
pubmed: 28434176
Ann Surg Oncol. 2012 Feb;19(2):577-83
pubmed: 21710322
J Nucl Med. 2020 Apr;61(4):577-583
pubmed: 31562221
Indian J Endocrinol Metab. 2018 Jul-Aug;22(4):535-541
pubmed: 30148104
Medicine (Baltimore). 2015 Oct;94(41):e1701
pubmed: 26469908
J Radiol Prot. 2018 Mar;38(1):343-356
pubmed: 29339573
J Nucl Med. 2002 Feb;43(2):187-99
pubmed: 11850483
BMC Endocr Disord. 2021 Jan 7;21(1):3
pubmed: 33413316
EJNMMI Res. 2019 Jul 31;9(1):72
pubmed: 31367807